Provided are methods for analyzing and purifying degarelix or a pharmaceutically acceptable salt thereof containing at least one related impurity. Also provided are methods for analyzing and purifying degarelix or a pharmaceutically acceptable salt thereof containing compound A and/or compound D as an impurity. Further provided are degarelix or a pharmaceutically acceptable salt thereof prepared from and/or selected using the disclosed methods.

Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.

Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.

A steviol glycoside composition with reduced surface tension. The reduced surface tension steviol glycoside composition includes an aqueous solution of a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension. Method for reducing surface tension in a steviol glycoside solution includes contacting a steviol glycoside and a surface tension reducing compound.

A steviol glycoside composition with reduced surface tension. The reduced surface tension steviol glycoside composition includes an aqueous solution of a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension. Method for reducing surface tension in a steviol glycoside solution includes contacting a steviol glycoside and a surface tension reducing compound.

The objective of the present invention is to provide a method of producing each high purity imidazole dipeptide in large quantities on an industrial scale, regardless of the type of animal extract employed. The objective is achieved by a method of producing a purified imidazole dipeptide composition, including the step (1) of subjecting an animal extract treatment solution containing at least two types of imidazole dipeptides to adsorption treatment carried out by bringing the solution into contact with a hydrophobic adsorption resin to adsorb the imidazole dipeptides onto the hydrophobic adsorption resin; and the step (2) of subjecting the hydrophobic adsorption resin adsorbing the imidazole dipeptides to elution treatment using an aqueous solution to mutually separate and collect the imidazole dipeptides to purify an imidazole dipeptide.

The present disclosure provides methods for purifying multispecific antibodies from a mispaired variant thereof by performing a multi-mode chromatography.

The present invention relates to a purification process of recombinant antibody fragments from inclusion bodies expressed in microbial cells. More particularly, the present invention relates to a process for purification of recombinant humanized (rHu) antibody fragment, Ranibizumab from inclusion bodies expressed in microbial cells.

The present invention relates to a purification process of recombinant antibody fragments from inclusion bodies expressed in microbial cells. More particularly, the present invention relates to a process for purification of recombinant humanized (rHu) antibody fragment, Ranibizumab from inclusion bodies expressed in microbial cells.

The invention relates to fusion polypeptides, nucleic acid molecules encoding said fusion polypeptides and genetically modified cells including said nucleic acid molecules. Moreover, the invention relates to a method for preparing target polypeptides using the fusion polypeptides.